Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants

Carl T. D'Angio, Roy J. Heyne, Shahnaz Duara, Lucy C. Holmes, T. Michael O'Shea, Hongyue Wang, Dongwen Wang, Pablo J. Sánchez, Robert C. Welliver, Rita M. Ryan, Kenneth C. Schnabel, Caroline B. Hall

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Influenza vaccine immunogenicity in premature infants is incompletely characterized. Objective: To assess the immunogenicity of trivalent, inactivated influenza vaccine (TIV) in extremely low-birth-weight (≤1000 g birth weight) premature (<30 weeks gestation) infants. We hypothesized that geometric mean titers of influenza antibody would be lower in premature than in full-term (FT) (37 week) infants. Design/Methods: In this prospective multicenter study, former premature and FT infants who were 6 to 17 months of age received 2 doses of TIV during the 2006-2007 or 2007-2008 influenza seasons. Sera were drawn before dose 1, and 4 to 6 weeks after dose 2. Antibody was measured by hemagglutination inhibition. Results: Over 2 years, 41 premature and 42 FT infants were enrolled; 36 and 33 of these infants, respectively, had postvaccination titers available. Premature infants weighed less (mean, 1.3-1.8 kg difference) at the time of immunization than FT infants. Prevaccination titers did not differ between groups. Premature infants had higher postvaccination antibody geometric mean titers than FT infants to H1 (2006-2007, 1:513 vs. 1:91, P = 0.03; 2007-2008, 1:363 vs. 1:189, P = 0.02) and B/Victoria (2006-2007, 1:51 vs. 1:10, P = 0.02). More premature than FT infants had antibody titers 1:32 to B/Victoria (85% vs. 60%, P = 0.04) in 2007-2008. Two (5%) premature and 8 (19%) FT infants had adverse events, primarily fever, within 72 hours after vaccination. No child had medically diagnosed influenza. Conclusions: Former premature infants had antibody responses to 2 TIV doses higher than or equal to those of FT children. Two TIV doses are immunogenic and well tolerated in extremely low-birth-weight, premature infants 6 to 17 months old.

Original languageEnglish
Pages (from-to)570-574
Number of pages5
JournalPediatric Infectious Disease Journal
Volume30
Issue number7
DOIs
StatePublished - Jul 1 2011

Fingerprint

Influenza Vaccines
Low Birth Weight Infant
Inactivated Vaccines
Premature Infants
Human Influenza
Antibodies
Victoria
Extremely Low Birth Weight Infant
Hemagglutination
Birth Weight
Multicenter Studies
Antibody Formation
Immunization
Vaccination
Fever
Prospective Studies
Pregnancy

Keywords

  • immunization
  • influenza vaccines
  • premature infant
  • vaccines
  • very-low-birth-weight infant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants. / D'Angio, Carl T.; Heyne, Roy J.; Duara, Shahnaz; Holmes, Lucy C.; O'Shea, T. Michael; Wang, Hongyue; Wang, Dongwen; Sánchez, Pablo J.; Welliver, Robert C.; Ryan, Rita M.; Schnabel, Kenneth C.; Hall, Caroline B.

In: Pediatric Infectious Disease Journal, Vol. 30, No. 7, 01.07.2011, p. 570-574.

Research output: Contribution to journalArticle

D'Angio, CT, Heyne, RJ, Duara, S, Holmes, LC, O'Shea, TM, Wang, H, Wang, D, Sánchez, PJ, Welliver, RC, Ryan, RM, Schnabel, KC & Hall, CB 2011, 'Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants', Pediatric Infectious Disease Journal, vol. 30, no. 7, pp. 570-574. https://doi.org/10.1097/INF.0b013e31820c1fdf
D'Angio, Carl T. ; Heyne, Roy J. ; Duara, Shahnaz ; Holmes, Lucy C. ; O'Shea, T. Michael ; Wang, Hongyue ; Wang, Dongwen ; Sánchez, Pablo J. ; Welliver, Robert C. ; Ryan, Rita M. ; Schnabel, Kenneth C. ; Hall, Caroline B. / Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants. In: Pediatric Infectious Disease Journal. 2011 ; Vol. 30, No. 7. pp. 570-574.
@article{8cfc5dc297f44a7bacb3b40d3fa332ae,
title = "Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants",
abstract = "Background: Influenza vaccine immunogenicity in premature infants is incompletely characterized. Objective: To assess the immunogenicity of trivalent, inactivated influenza vaccine (TIV) in extremely low-birth-weight (≤1000 g birth weight) premature (<30 weeks gestation) infants. We hypothesized that geometric mean titers of influenza antibody would be lower in premature than in full-term (FT) (37 week) infants. Design/Methods: In this prospective multicenter study, former premature and FT infants who were 6 to 17 months of age received 2 doses of TIV during the 2006-2007 or 2007-2008 influenza seasons. Sera were drawn before dose 1, and 4 to 6 weeks after dose 2. Antibody was measured by hemagglutination inhibition. Results: Over 2 years, 41 premature and 42 FT infants were enrolled; 36 and 33 of these infants, respectively, had postvaccination titers available. Premature infants weighed less (mean, 1.3-1.8 kg difference) at the time of immunization than FT infants. Prevaccination titers did not differ between groups. Premature infants had higher postvaccination antibody geometric mean titers than FT infants to H1 (2006-2007, 1:513 vs. 1:91, P = 0.03; 2007-2008, 1:363 vs. 1:189, P = 0.02) and B/Victoria (2006-2007, 1:51 vs. 1:10, P = 0.02). More premature than FT infants had antibody titers 1:32 to B/Victoria (85{\%} vs. 60{\%}, P = 0.04) in 2007-2008. Two (5{\%}) premature and 8 (19{\%}) FT infants had adverse events, primarily fever, within 72 hours after vaccination. No child had medically diagnosed influenza. Conclusions: Former premature infants had antibody responses to 2 TIV doses higher than or equal to those of FT children. Two TIV doses are immunogenic and well tolerated in extremely low-birth-weight, premature infants 6 to 17 months old.",
keywords = "immunization, influenza vaccines, premature infant, vaccines, very-low-birth-weight infant",
author = "D'Angio, {Carl T.} and Heyne, {Roy J.} and Shahnaz Duara and Holmes, {Lucy C.} and O'Shea, {T. Michael} and Hongyue Wang and Dongwen Wang and S{\'a}nchez, {Pablo J.} and Welliver, {Robert C.} and Ryan, {Rita M.} and Schnabel, {Kenneth C.} and Hall, {Caroline B.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1097/INF.0b013e31820c1fdf",
language = "English",
volume = "30",
pages = "570--574",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants

AU - D'Angio, Carl T.

AU - Heyne, Roy J.

AU - Duara, Shahnaz

AU - Holmes, Lucy C.

AU - O'Shea, T. Michael

AU - Wang, Hongyue

AU - Wang, Dongwen

AU - Sánchez, Pablo J.

AU - Welliver, Robert C.

AU - Ryan, Rita M.

AU - Schnabel, Kenneth C.

AU - Hall, Caroline B.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Background: Influenza vaccine immunogenicity in premature infants is incompletely characterized. Objective: To assess the immunogenicity of trivalent, inactivated influenza vaccine (TIV) in extremely low-birth-weight (≤1000 g birth weight) premature (<30 weeks gestation) infants. We hypothesized that geometric mean titers of influenza antibody would be lower in premature than in full-term (FT) (37 week) infants. Design/Methods: In this prospective multicenter study, former premature and FT infants who were 6 to 17 months of age received 2 doses of TIV during the 2006-2007 or 2007-2008 influenza seasons. Sera were drawn before dose 1, and 4 to 6 weeks after dose 2. Antibody was measured by hemagglutination inhibition. Results: Over 2 years, 41 premature and 42 FT infants were enrolled; 36 and 33 of these infants, respectively, had postvaccination titers available. Premature infants weighed less (mean, 1.3-1.8 kg difference) at the time of immunization than FT infants. Prevaccination titers did not differ between groups. Premature infants had higher postvaccination antibody geometric mean titers than FT infants to H1 (2006-2007, 1:513 vs. 1:91, P = 0.03; 2007-2008, 1:363 vs. 1:189, P = 0.02) and B/Victoria (2006-2007, 1:51 vs. 1:10, P = 0.02). More premature than FT infants had antibody titers 1:32 to B/Victoria (85% vs. 60%, P = 0.04) in 2007-2008. Two (5%) premature and 8 (19%) FT infants had adverse events, primarily fever, within 72 hours after vaccination. No child had medically diagnosed influenza. Conclusions: Former premature infants had antibody responses to 2 TIV doses higher than or equal to those of FT children. Two TIV doses are immunogenic and well tolerated in extremely low-birth-weight, premature infants 6 to 17 months old.

AB - Background: Influenza vaccine immunogenicity in premature infants is incompletely characterized. Objective: To assess the immunogenicity of trivalent, inactivated influenza vaccine (TIV) in extremely low-birth-weight (≤1000 g birth weight) premature (<30 weeks gestation) infants. We hypothesized that geometric mean titers of influenza antibody would be lower in premature than in full-term (FT) (37 week) infants. Design/Methods: In this prospective multicenter study, former premature and FT infants who were 6 to 17 months of age received 2 doses of TIV during the 2006-2007 or 2007-2008 influenza seasons. Sera were drawn before dose 1, and 4 to 6 weeks after dose 2. Antibody was measured by hemagglutination inhibition. Results: Over 2 years, 41 premature and 42 FT infants were enrolled; 36 and 33 of these infants, respectively, had postvaccination titers available. Premature infants weighed less (mean, 1.3-1.8 kg difference) at the time of immunization than FT infants. Prevaccination titers did not differ between groups. Premature infants had higher postvaccination antibody geometric mean titers than FT infants to H1 (2006-2007, 1:513 vs. 1:91, P = 0.03; 2007-2008, 1:363 vs. 1:189, P = 0.02) and B/Victoria (2006-2007, 1:51 vs. 1:10, P = 0.02). More premature than FT infants had antibody titers 1:32 to B/Victoria (85% vs. 60%, P = 0.04) in 2007-2008. Two (5%) premature and 8 (19%) FT infants had adverse events, primarily fever, within 72 hours after vaccination. No child had medically diagnosed influenza. Conclusions: Former premature infants had antibody responses to 2 TIV doses higher than or equal to those of FT children. Two TIV doses are immunogenic and well tolerated in extremely low-birth-weight, premature infants 6 to 17 months old.

KW - immunization

KW - influenza vaccines

KW - premature infant

KW - vaccines

KW - very-low-birth-weight infant

UR - http://www.scopus.com/inward/record.url?scp=79959731560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959731560&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e31820c1fdf

DO - 10.1097/INF.0b013e31820c1fdf

M3 - Article

C2 - 21273938

AN - SCOPUS:79959731560

VL - 30

SP - 570

EP - 574

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 7

ER -